Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY .   The STREAMWAY System transforms the collection, measurement and disposal of healthcare waste fluid making it safer, easier and environmentally

MINNEAPOLIS , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the

MINNEAPOLIS , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019 , the Company repaid the remaining

NEW YORK , Sept. 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative company focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcome, today announces it has selected the corporate

Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 5:30PM Today MINNEAPOLIS , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional

Conference Call to be held August 19, 2019, at 4:30pm Eastern Time MINNEAPOLIS , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the

MINNEAPOLIS , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals.

Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS , July 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a

PITTSBURGH , July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products

MINNEAPOLIS, Minn ., June 26, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement